Comparison of efficacy and safety of sitagliptin or ipragliflozin in type 2 diabetic patients with insulin therapy
Not Applicable
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000014139
- Lead Sponsor
- Yokohama City University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Not provided
Exclusion Criteria
Patients whose BMI is less than 18 Patients with moderale renal disfunction Patients with sever liver disfunction Patients who have experienced severe diabetic ketosis, diabetic coma, or past history of pre-coma prior to 3 months Patients with sever infection, operation, trauma, and urine and genital infection Female patients who have pregnancy or possibilty of pregnancy, or are under lactation Patients who are considered to be not eligible to the study by the doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HbA1c(non-inferiority margin is 0.4%)
- Secondary Outcome Measures
Name Time Method